PRI-002, Oral Therapy Candidate for Alzheimer’s, Deemed Safe in Phase 1 Trial
Alzheimer’s oral therapy candidate PRI-002, being developed by Priavoid, has proven safe for human use in healthy volunteers during a Phase 1 clinical trial. These positive trial results provide important evidence that supports progressing…